NASDAQ:ZLAB Zai Lab (ZLAB) Stock Forecast, Price & News $35.14 -0.56 (-1.57%) (As of 12:58 PM ET) Add Compare Share Share Today's Range$33.50▼$35.8050-Day Range$30.78▼$39.6752-Week Range$20.98▼$53.95Volume158,827 shsAverage Volume685,035 shsMarket Capitalization$3.44 billionP/E RatioN/ADividend YieldN/APrice Target$94.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Zai Lab MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside174.1% Upside$94.33 Price TargetShort InterestHealthy3.34% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.75Based on 6 Articles This WeekInsider TradingSelling Shares$322,981 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.08) to ($2.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.18 out of 5 starsMedical Sector296th out of 980 stocksPharmaceutical Preparations Industry136th out of 485 stocks 3.5 Analyst's Opinion Consensus RatingZai Lab has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $94.33, Zai Lab has a forecasted upside of 174.1% from its current price of $34.42.Amount of Analyst CoverageZai Lab has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.34% of the outstanding shares of Zai Lab have been sold short.Short Interest Ratio / Days to CoverZai Lab has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Zai Lab has recently decreased by 1.80%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldZai Lab does not currently pay a dividend.Dividend GrowthZai Lab does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZLAB. Previous Next 3.2 News and Social Media Coverage News SentimentZai Lab has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Zai Lab this week, compared to 3 articles on an average week.Search Interest3 people have searched for ZLAB on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zai Lab insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $322,981.00 in company stock.Percentage Held by InsidersOnly 5.23% of the stock of Zai Lab is held by insiders.Percentage Held by Institutions59.46% of the stock of Zai Lab is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zai Lab are expected to grow in the coming year, from ($3.08) to ($2.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zai Lab is -8.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zai Lab is -8.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZai Lab has a P/B Ratio of 3.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Zai Lab (NASDAQ:ZLAB) StockZai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.Read More Receive ZLAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter. Email Address ZLAB Stock News HeadlinesJune 2, 2023 | finanznachrichten.deZai Lab Limited: Zai Lab to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual MeetingJune 1, 2023 | finance.yahoo.comZai Lab to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual MeetingJune 5, 2023 | Edge On The Street (Ad)Investor Alert: EV Initiatives Create Unsustainable Demand For LithiumThe soaring demand for lithium is driven by worldwide demand for electric vehicles (EVs). Lithium is ideal for electric cars. It's lightweight, stores lots of energy and is rechargeable. Sales of EVs are expected to increase 10-fold by 2030 and estimates are that 1 in 2 cars sold will be electric by 2040.June 1, 2023 | americanbankingnews.comZai Lab (NASDAQ:ZLAB) Shares Down 5.4% May 29, 2023 | markets.businessinsider.comZai Lab (ZLAB): New Buy Recommendation for This Technology GiantMay 25, 2023 | finance.yahoo.comZai Lab Announces Participation in June Investor ConferencesMay 24, 2023 | finance.yahoo.com12 Best Chinese Stocks to Buy NowMay 24, 2023 | americanbankingnews.comZai Lab (NASDAQ:ZLAB) Shares Gap Up to $31.50June 5, 2023 | Edge On The Street (Ad)Investor Alert: EV Initiatives Create Unsustainable Demand For LithiumThe soaring demand for lithium is driven by worldwide demand for electric vehicles (EVs). Lithium is ideal for electric cars. It's lightweight, stores lots of energy and is rechargeable. Sales of EVs are expected to increase 10-fold by 2030 and estimates are that 1 in 2 cars sold will be electric by 2040.May 21, 2023 | fool.comZai Lab (NASDAQ: ZLAB)May 18, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG) and Zai Lab (ZLAB)May 18, 2023 | technews.tmcnet.comZai Lab Announces That Repotrectinib Granted Priority Review by China's NMPAMay 18, 2023 | markets.businessinsider.comZai Lab Reports CDE's Decision To Grant Priority Review To Repotrectinib In ChinaMay 18, 2023 | finance.yahoo.comZai Lab Announces That Repotrectinib Granted Priority Review by China’s NMPAMay 17, 2023 | americanbankingnews.comZai Lab Limited Forecasted to Post Q2 2023 Earnings of ($0.73) Per Share (NASDAQ:ZLAB)May 15, 2023 | finance.yahoo.comInvestors push Zai Lab (NASDAQ:ZLAB) 9.3% lower this week, company's increasing losses might be to blameMay 14, 2023 | americanbankingnews.comCitigroup Cuts Zai Lab (NASDAQ:ZLAB) Price Target to $130.00May 10, 2023 | msn.comZai Lab: Q1 Earnings InsightsMay 10, 2023 | finanznachrichten.deZai Lab Limited: Zai Lab Announces First Quarter 2023 Financial Results and Corporate UpdatesMay 9, 2023 | finance.yahoo.comZai Lab Announces First Quarter 2023 Financial Results and Corporate UpdatesMay 9, 2023 | finance.yahoo.comZai Lab Announces First Quarter 2023 Financial Results and Corporate UpdatesMay 8, 2023 | msn.comEarnings Preview For Zai LabMay 8, 2023 | americanbankingnews.comZai Lab (ZLAB) Scheduled to Post Quarterly Earnings on TuesdayMay 5, 2023 | nasdaq.comZai Lab (ZLAB) Shares Cross Above 200 DMAMay 2, 2023 | americanbankingnews.comJefferies Financial Group Comments on Zai Lab Limited's Q1 2023 Earnings (NASDAQ:ZLAB)April 30, 2023 | americanbankingnews.comBrokers Issue Forecasts for Zai Lab Limited's Q1 2024 Earnings (NASDAQ:ZLAB)April 27, 2023 | tmcnet.comZai Lab Announces Strategic Partnership and Global LicenseSee More Headlines ZLAB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZLAB Company Calendar Last Earnings5/09/2023Today6/05/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ZLAB CUSIPN/A CIK1704292 Webwww.zailaboratory.com Phone862161632588Fax86-21-6163-2570Employees2,036Year FoundedN/APrice Target and Rating Average Stock Price Forecast$94.33 High Stock Price Forecast$130.00 Low Stock Price Forecast$70.00 Forecasted Upside/Downside+173.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($4.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-443,290,000.00 Net Margins-177.42% Pretax Margin-177.42% Return on Equity-37.58% Return on Assets-32.11% Debt Debt-to-Equity RatioN/A Current Ratio8.61 Quick Ratio8.30 Sales & Book Value Annual Sales$215.04 million Price / Sales15.74 Cash FlowN/A Price / Cash FlowN/A Book Value$10.68 per share Price / Book3.24Miscellaneous Outstanding Shares97,910,000Free Float92,788,000Market Cap$3.38 billion OptionableOptionable Beta1.15 Key ExecutivesYing DuChairman & Chief Executive OfficerRafael G. AmadoPresidentJoshua L. SmileyChief Operating OfficerBilly ChoChief Financial OfficerNing XuExecutive VP & Head-Clinical OperationsKey CompetitorsAxsome TherapeuticsNASDAQ:AXSMImmunoGenNASDAQ:IMGNPTC TherapeuticsNASDAQ:PTCTSage TherapeuticsNASDAQ:SAGEBausch Health CompaniesNYSE:BHCView All CompetitorsInsiders & InstitutionsAmeriprise Financial Inc.Bought 3,539 shares on 5/22/2023Ownership: 0.021%JPMorgan Chase & Co.Bought 194,063 shares on 5/18/2023Ownership: 0.292%Geode Capital Management LLCBought 7,694 shares on 5/16/2023Ownership: 0.474%Susquehanna International Group Ltd.Bought 28,807 shares on 5/16/2023Ownership: 0.029%Alberta Investment Management CorpBought 22,000 shares on 5/16/2023Ownership: 0.022%View All Insider TransactionsView All Institutional Transactions ZLAB Stock - Frequently Asked Questions Should I buy or sell Zai Lab stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZLAB shares. View ZLAB analyst ratings or view top-rated stocks. What is Zai Lab's stock price forecast for 2023? 2 brokerages have issued twelve-month target prices for Zai Lab's shares. Their ZLAB share price forecasts range from $70.00 to $130.00. On average, they anticipate the company's stock price to reach $94.33 in the next year. This suggests a possible upside of 164.2% from the stock's current price. View analysts price targets for ZLAB or view top-rated stocks among Wall Street analysts. How have ZLAB shares performed in 2023? Zai Lab's stock was trading at $30.70 on January 1st, 2023. Since then, ZLAB stock has increased by 16.3% and is now trading at $35.70. View the best growth stocks for 2023 here. When is Zai Lab's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our ZLAB earnings forecast. How were Zai Lab's earnings last quarter? Zai Lab Limited (NASDAQ:ZLAB) posted its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.51) earnings per share for the quarter, beating analysts' consensus estimates of ($0.94) by $0.43. The business had revenue of $62.80 million for the quarter, compared to the consensus estimate of $65.21 million. Zai Lab had a negative trailing twelve-month return on equity of 37.58% and a negative net margin of 177.42%. What ETFs hold Zai Lab's stock? ETFs with the largest weight of Zai Lab (NASDAQ:ZLAB) stock in their portfolio include Global X China Biotech Innovation ETF (CHB), ETFMG Treatments Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Global X MSCI China Health Care ETF (CHIH), Virtus LifeSci Biotech Products ETF (BBP), Loncar China Biopharma ETF (CHNA), Invesco Golden Dragon China ETF (PGJ) and KraneShares MSCI All China Health Care Index ETF (KURE). What other stocks do shareholders of Zai Lab own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN). When did Zai Lab IPO? (ZLAB) raised $100 million in an initial public offering on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO. What is Zai Lab's stock symbol? Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB." Who are Zai Lab's major shareholders? Zai Lab's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.48%), FMR LLC (3.14%), Price T Rowe Associates Inc. MD (2.46%), Segantii Capital Management Ltd (2.33%), Credit Suisse AG (2.25%) and Genesis Investment Management LLP (1.60%). Insiders that own company stock include Frazor Titus Edmondson III, Harald Reinhart, John D Diekman, John D Diekman, Kai-Xian Chen, Peter Wirth, Tao Fu, William Ki Chul Cho, William Lis and Ying Du. View institutional ownership trends. How do I buy shares of Zai Lab? Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Zai Lab's stock price today? One share of ZLAB stock can currently be purchased for approximately $35.70. How much money does Zai Lab make? Zai Lab (NASDAQ:ZLAB) has a market capitalization of $3.50 billion and generates $215.04 million in revenue each year. The company earns $-443,290,000.00 in net income (profit) each year or ($4.28) on an earnings per share basis. How many employees does Zai Lab have? The company employs 2,036 workers across the globe. How can I contact Zai Lab? Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The official website for the company is www.zailaboratory.com. The company can be reached via phone at 862161632588, via email at jsteier@burnsmc.com, or via fax at 86-21-6163-2570. This page (NASDAQ:ZLAB) was last updated on 6/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zai Lab Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.